We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+29.22%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$514M
AUM Growth
+$32.4M
Cap. Flow
-$86.5M
Cap. Flow %
-16.83%
Top 10 Hldgs %
73.17%
Holding
39
New
7
Increased
8
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$21.7M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$9.08M
3
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$7.08M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.05M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$6.73M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$71.2M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$13M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$10.9M
4
PRQR icon
ProQR Therapeutics
PRQR
+$9.44M
5
ARRY
Array Biopharma Inc
ARRY
+$8.32M

Sector Composition

Rank Sector Weight
1 Healthcare 70.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$614M
$78M 15.18%
6,082,009
-600,887
-9% -$6.88M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$58.7M 11.42%
8,596,772
– –
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$55.7M 10.83%
11,772,335
-2,104,178
-15% -$8.32M
LGND icon
4
Ligand Pharmaceuticals
LGND
$5.94B
$45.8M 8.9%
1,378,681
-398,666
-22% -$13M
OMED
5
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$29.9M 5.82%
1,374,815
+86,968
+7% +$1.78M
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
$26.1M 5.09%
2,293,710
+649,164
+39% +$7.05M
FPRX
7
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$22.3M 4.34%
826,332
-635,568
-43% -$10.9M
FWP
8
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$21.9M 4.26%
+150,340
New +$21.7M
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$19.6M 3.81%
2,443,100
+916,100
+60% +$3.93M
GYRE icon
10
Gyre Therapeutics
GYRE
$648M
$17.5M 3.4%
8,451
– –
CNCE
11
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$16.1M 3.13%
1,206,459
– –
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$14M 2.72%
1,190,702
-1,500
-0.1% -$17.5K
VTAE
13
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$12.5M 2.44%
753,935
+87,935
+13% +$1.29M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.2B
$12.2M 2.38%
+618,224
New +$9.08M
QLTI
15
DELISTED
QLT Inc
QLTI
$10.6M 2.07%
2,650,563
+557,000
+27% +$2.18M
ONCT
16
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$8.11M 1.58%
+7,937
New +$7.08M
VIRX
17
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8M 1.56%
+14,933
New +$6.73M
EXEL icon
18
Exelixis
EXEL
$14.1B
$6.04M 1.18%
+4,195,352
New +$6.54M
ARQL
19
DELISTED
Arqule Inc
ARQL
$5.76M 1.12%
4,723,811
+422,924
+10% +$500K
SVRA icon
20
Savara
SVRA
$1.14B
$4.08M 0.79%
+104,166
New +$3.64M
ACHV icon
21
Achieve Life Sciences
ACHV
$647M
$3.13M 0.61%
622
+321
+107% +$1.57M
BLRX
22
BioLineRX
BLRX
$11.7M
$2.43M 0.47%
2,502
– –
KBIO
23
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$2.01M 0.39%
145,250
– –
AKAO
24
DELISTED
Achaogen Inc
AKAO
$1.78M 0.35%
136,600
– –
TBRA
25
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$1.72M 0.33%
209,169
-80,508
-28% -$693K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2014 Portfolio in Review

As of Q4 2014, BVF Inc held 39 positions worth $514M, up 6.7% from $482M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BVF Inc withdrew a net $86.5M in Q4 2014, closing 8 positions and reducing 6 holdings. Its most notable exit was RECEPTOS INC COM STK (DE), an estimated $71.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 65% a quarter earlier.

Against the trend, BVF Inc opened a new position in Forward Pharma A/S American Depositary Shares worth $21.9M.

  • BVF Inc's largest Q4 2014 buy was Forward Pharma A/S American Depositary Shares: 150,340 shares worth $21.9M.
  • BVF Inc added most to Cascadian Therapeutics, Inc. in Q4 2014, an estimated $7.05M increase.
  • BVF Inc's biggest Q4 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $13M.
  • BVF Inc fully exited RECEPTOS INC COM STK (DE) in Q4 2014, selling an estimated $71.2M.
  • BVF Inc's ten largest holdings make up 73% of its $514M portfolio in Q4 2014.
  • BVF Inc opened 7 new positions and closed 8 in Q4 2014.
  • BVF Inc's portfolio value rose 6.7% quarter-over-quarter to $514M.

Based on BVF Inc's 13F filing for Q4 2014, filed 17 Feb 2015.